Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.260
-0.030 (-2.33%)
May 14, 2026, 2:03 PM EDT - Market open
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 25 employees as of December 31, 2025. The number of employees decreased by 12 or -32.43% compared to the previous year.
Employees
25
Change
-12
Growth
-32.43%
Revenue / Employee
$3,600
Profits / Employee
-$938,840
Market Cap
39.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | 32 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| Plus Therapeutics | 28 |
| Daré Bioscience | 24 |
| INmune Bio | 21 |
| RenovoRx | 17 |
| Nutriband | 13 |
ATNM News
- 8 days ago - Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - PRNewsWire
- 22 days ago - Actinium presents data from Actimab-A studies at AACR - TheFly
- 22 days ago - Actinium presents preclinical results for ATNM-400 at AACR - TheFly
- 22 days ago - Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 22 days ago - Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PRNewsWire
- 4 weeks ago - NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225 - Business Wire
- 5 weeks ago - Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PRNewsWire
- 3 months ago - BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - Business Wire